870 results on '"Leufkens, Hubert G. M."'
Search Results
2. Medicine shortages: impact behind numbers
3. The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report
4. Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019
5. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
6. Impact of medicine shortages on patients - a framework and application in the Netherlands
7. The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
8. Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
9. Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
10. Thoughts on Pharmacovigilance in the Future: There Are More Weber-Effects
11. Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study
12. Comment on “Deterministic Sensitivity Analysis Under Ignorance”
13. Effects of over-the-counter sales restriction of antibiotics on substitution with medicines for symptoms relief of cold in Mexico and Brazil : time series analysis
14. Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana
15. Prescribing patterns and compliance with World Health Organization recommendations for the management of severe malaria: a modified cohort event monitoring study in public health facilities in Ghana and Uganda
16. Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences
17. Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems
18. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns
19. Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients
20. Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
21. Age-Specific Antibiotic Prescribing and Adherence to Guidelines in Pediatric Patients in Primary Care
22. Sources of heterogeneity in case-control studies on associations between statins, ACE-inhibitors, and proton pump inhibitors and risk of pneumonia
23. Pharmacological vs. classical approaches in the design of first in man clinical drug trials
24. Reviewers of manuscripts submitted in 2016: With appreciation
25. Thoughts on Pharmacovigilance in the Future: There Are More Weber-Effects
26. Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: a comparison with standard approved cancer drugs
27. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®
28. Healthcare Professionals' Views on the Management of Medication Complexities in the Elderly With Mental Health Disorders: A Cross-Sectional Study
29. Addressing uncertainty in relative effectiveness assessments by HTA organizations
30. Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies
31. Additional file 1 of Impact of medicine shortages on patients - a framework and application in the Netherlands
32. Additional file 2 of The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
33. Additional file 1 of The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
34. Use of incretin agents and risk of acute and chronic pancreatitis: A population‐based cohort study
35. Long‐term use of dipeptidyl peptidase‐4 inhibitors and risk of fracture: A retrospective population‐based cohort study
36. Differences in VigiBase® reporting of aminoglycoside and capreomycin‐suspected ototoxicity during tuberculosis treatment
37. Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement.
38. Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis
39. Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
40. Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
41. Comment on 'Deterministic Sensitivity Analysis Under Ignorance'
42. Functional Foods: The Case for Closer Evaluation
43. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders
44. Regulatory safety learning driven by the mechanism of action: the case of TNF-α inhibitors
45. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study†
46. Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures
47. Validity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database
48. Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom
49. Switching TNFα inhibitors: Patterns and determinants
50. Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.